Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II

por Twelves, C J, Gardner, C, Flavin, A, Sludden, J, Dennis, I, Bono, J de, Beale, P, Vasey, P, Hutchison, C, Macham, M A, Rodriguez, A, Judson, I, Bleehen, N M
Publicado 1999

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

por Benson, C, White, J, Bono, J De, O'Donnell, A, Raynaud, F, Cruickshank, C, McGrath, H, Walton, M, Workman, P, Kaye, S, Cassidy, J, Gianella-Borradori, A, Judson, I, Twelves, C
Publicado 2007